Journal of Nuclear Cardiology

, Volume 24, Issue 1, pp 86–99 | Cite as

Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation

  • Michael T. OsborneEmail author
  • Edward A. Hulten
  • Venkatesh L. Murthy
  • Hicham Skali
  • Viviany R. Taqueti
  • Sharmila Dorbala
  • Marcelo F. DiCarli
  • Ron Blankstein
CME Article Review Article


Although the number of clinical applications for fluorine-18 fluorodeoxyglucose (18F-FDG) cardiac positron emission tomography (PET) has continued to grow, there remains a lack of consensus regarding the ideal method of suppressing normal myocardial glucose utilization for image optimization. This review describes various patient preparation protocols that have been used as well as the success rates achieved in different studies. Collectively, the available literature supports using a high-fat, no-carbohydrate diet for at least two meals with a fast of 4-12 hours prior to 18F-FDG PET imaging and suggests that isolated fasting for less than 12 hours and supplementation with food or drink just prior to imaging should be avoided. Each institution should adopt a protocol and continuously monitor its effectiveness with a goal to achieve adequate myocardial suppression in greater than 80% of patients.


PET imaging fluorodeoxyglucose (FDG) metabolism inflammation 





Positron emission tomography



Dr Murthy owns stock in General Electric, Cardinal Health and Mallinckrodt. Drs Osborne, Hulten, Skali, Taqueti, Dorbala, DiCarli and Blankstein have no disclosures or conflicts of interest related to this publication. The opinions and assertions contained herein are the authors’ alone and do not represent the views of the Walter Reed National Military Medical Center, the US Army, or the Department of Defense.

Supplementary material

12350_2016_502_MOESM1_ESM.pptx (203 kb)
Supplementary material 1 (PPTX 203 kb)


  1. 1.
    Blankstein R, Lundbye J, Heller G. Proceedings of the ASNC cardiac PET summit meeting, May 12 2014, Baltimore MD. J Nucl Cardiol 2015;22:720–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Cautela J, Alessandrini S, Cammilleri S, Giorgi R, Richet H, Casalta JP, et al. Diagnostic yield of FDG positron-emission tomography/computed tomography in patients with CEID infection: A pilot study. Europace 2013;15:252–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonnier L, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: Increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;21:166–74.Google Scholar
  5. 5.
    Morooka M, Moroi M, Ito K, Wu J, Nakagawa T, Kubota K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesion of cardiac sarcoidosis. EJNMMI Res 2014;4:1.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Demeure F, Hanin FX, Bol A, Vincent MF, Pouleur AC, Gerber B, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: Implications for vulnerable coronary plaque imaging. J Nucl Med 2014;55:1629–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999;99:578–88.CrossRefPubMedGoogle Scholar
  10. 10.
    Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5.PubMedGoogle Scholar
  11. 11.
    Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767–74.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yamada S, Kubota K, Kubota K, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–6.PubMedGoogle Scholar
  13. 13.
    Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography-computed tomography for imaging inflammatory cardiovascular disease Circ J. 2014;78:1302–10.CrossRefPubMedGoogle Scholar
  14. 14.
    Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel JH, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; A comparative study using different protocols. Eur J Nucl Med 1997;24:35–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Garfein O. Current concepts in cardiovascular physiology. Burlington: Elsevier Science; 2012. p. 565.Google Scholar
  16. 16.
    Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nuc Med 2015. doi: 10.1097/RLU.0000000000001063.Google Scholar
  17. 17.
    Harisankar CN, Mittal BR, Agarwal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG Uptake. J Nucl Cardiol 2011;18:926–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Soussan M, Brilley PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Balink H, Hut E, Pol T, Flokstra FJ, Roef M. Suppression of 18F-FDG myocardial uptake using a fat-allowed, carbohydrate-restricted diet. J Nucl Med Technol 2011;39:185–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of fluoro-2-deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014;29:140–5.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Coulden R, Chung P, Sonnex E, Ibrahim Q, Maguire C, Abele J. Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet. Eur Radiol 2012;22:2221–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Scholtens AM, Verberne HJ, Budde RP, Lam MG. Additional heparin pre-administration improves cardiac glucose metabolism over low carbohydrate diet alone in 18F-FDG-PET imaging. J Nucl Med 2016;57:568–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Lum DP, Wandell S, Ko J, Koel MN. Reduction of myocardial 2-deoxy-2[18F]fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Lee HY, Nam HY, Shin SK. Comparison of myocardial F-18 uptake between overnight and non-overnight fasting in non-diabetic healthy subjects. Jpn J Radiol 2015;33:385–91.CrossRefPubMedGoogle Scholar
  27. 27.
    Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531–3.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gaeta C, Fernández Y, Pavía J, et al. Reduced myocardial 18F-FDG uptake after calcium channel blocker administration: Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging 2011;38:2018–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Japanese Society of Sarcoidosis and Other Granulomatous Disorders. Diagnostic standard and guideline for sarcoidosis. Tokyo: Japanese Ministry of Health, Labour and Welfare; 2006. p. 6.Google Scholar
  30. 30.
    Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578–83.CrossRefPubMedGoogle Scholar
  31. 31.
    Patel MR, Cawley PC, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V, et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485–507.CrossRefPubMedGoogle Scholar
  33. 33.
    Vik-Mo H, Mjøs OD. Influence of free fatty acids on myocardial oxygen consumption and ischemic injury. Am J Cardiol 1981;2:361–5.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2016

Authors and Affiliations

  • Michael T. Osborne
    • 1
    • 2
    Email author
  • Edward A. Hulten
    • 3
  • Venkatesh L. Murthy
    • 4
    • 5
  • Hicham Skali
    • 2
  • Viviany R. Taqueti
    • 2
  • Sharmila Dorbala
    • 2
  • Marcelo F. DiCarli
    • 2
  • Ron Blankstein
    • 2
  1. 1.Cardiology Division, Department of MedicineMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Non-Invasive Cardiovascular Imaging Program, Departments of Medicine and RadiologyBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Cardiology Service, Division of MedicineWalter Reed National Military Medical Center and Uniformed Services University of Health SciencesBethesdaUSA
  4. 4.Division of Cardiovascular Medicine, Department of MedicineUniversity of MichiganAnn ArborUSA
  5. 5.Divisions of Nuclear Medicine and Cardiothoracic Imaging, Department of RadiologyUniversity of MichiganAnn ArborUSA

Personalised recommendations